Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Biotechnology
Neurology
Health
Pharmaceutical
Clinical Trials
birtamimab

More Like This

Business Wire logo

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Business Wire logo

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Business Wire logo

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Business Wire logo

Prothena Announces Corporate Restructuring

Business Wire logo

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Business Wire logo

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire logo

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Business Wire logo

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us